艾美疫苗(06660.HK):13價肺炎結合疫苗已提交上市註冊預申請
格隆匯3月1日丨艾美疫苗(06660.HK)發佈公吿,於2024年2月29日,集團13價肺炎結合疫苗,已提交上市註冊預申請,計劃本年度正式完成申報上市。
13價肺炎結合疫苗主要用於6周齡至5歲嬰幼兒和兒童,預防該疫苗包含的13種肺炎血清型引起的侵襲性疾病(包括菌血症性肺炎、腦膜炎、敗血症和菌血症)。肺炎疾病是導致5歲以下兒童發病和死亡的主要原因,世界衞生組織將兒童肺炎疾病列為需高度優先使用疫苗預防的疾病,並推薦使用13價肺炎結合疫苗進行接種。在世衞組織可用疫苗預防的疾病分級中,肺炎系列產品處於“極高度優先”級別。因此13價肺炎結合疫苗市場前景巨大,上市後將供不應求。集團肺炎系列疫苗GMP車間已建設完成,滿足國際化標準,該款13價肺炎結合疫苗的III期臨牀樣品均在標準化車間生產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.